Ebola

Chimerix to Report Second Quarter 2021 Financial Results and Provide an Operational Update on August 5, 2021

Retrieved on: 
Thursday, July 29, 2021

ET to report financial results for the second quarter ended June 30, 2021, and to provide an operational update.

Key Points: 
  • ET to report financial results for the second quarter ended June 30, 2021, and to provide an operational update.
  • A live audio webcast of the call will also be available on the Investors section of the Company's website, www.chimerix.com .
  • An archived webcast will be available on the Chimerix website approximately two hours after the event.
  • In June 2021, the U.S. Food and Drug Administration granted approval of TEMBEXA for the treatment of smallpox as a medical countermeasure.

GeoVax Announces Presentation of Sudan Ebolavirus Vaccine Data at the American Society for Virology Annual Meeting

Retrieved on: 
Thursday, July 22, 2021

ATLANTA, GA, July 22, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines, today announced the presentation of data from a study of its preventive vaccine against Sudan Ebolavirus (SUDV). The presentation titled “A single immunization of guinea pigs with a modified vaccinia Ankara virus producing Sudan virus-like particles protects from Sudan virus lethal challenge,” was delivered by Dr. Delphine Malherbe of the Bukreyev Lab, Department of Pathology, University of Texas Medical Branch, Galveston, Texas, during the Annual Meeting of the American Society for Virology, being held virtually July 19-23.

Key Points: 
  • Challenge of vaccinated animals with guinea pig-adapted SUDV demonstrated a complete protection against death and disease by the prime and the prime-boost regimens.
  • This is the first report that a replication-deficient MVA vector may confer full protection against SUDV after a single dose.
  • David Dodd, GeoVax President and CEO, further commented, The presentation of data from this study further validates our platform and approach to addressing Sudan virus, and we look forward to advancing our vaccine to non-human primate testing.
  • Sudan ebolavirus (SUDV) is one of six known viruses within the genus Ebolavirus (Filoviridae family) and causes Ebola virus disease in humans, with a fatality rate up to 73%.

EDCTP and CEPI Funding Moves IAVI's Lassa fever Vaccine Candidate Into Advanced Clinical Development

Retrieved on: 
Tuesday, June 15, 2021

Despite this disease burden, which is believed to be significantly underestimated, no vaccine for Lassa fever is currently available.

Key Points: 
  • Despite this disease burden, which is believed to be significantly underestimated, no vaccine for Lassa fever is currently available.
  • The joint award supports an international collaboration, called Lassa Fever Vaccine Efficacy and Prevention for West Africa (LEAP4WA), to conduct a Phase IIb clinical trial of IAVIs Lassa fever vaccine candidate among adults and children in Liberia, Nigeria, and Sierra Leone.
  • LEAP4WA builds on an existing partnership with CEPI that supports IAVI and a global consortium of partners to conduct Phase I and II clinical trials of IAVIs Lassa fever vaccine candidate.
  • We are excited to apply the recombinant VSV technology, used in the previously licensed Ebola vaccine called ERVEBO, for the development of a much-needed Lassa fever vaccine.

Chimerix Receives U.S. Food and Drug Administration Approval for TEMBEXA® (brincidofovir) for the Treatment of Smallpox

Retrieved on: 
Friday, June 4, 2021

In the pivotal studies in each model, TEMBEXA treatment resulted in statistically significant survival benefit versus placebo following delayed treatment after animals were infected with a lethal viral dose.

Key Points: 
  • In the pivotal studies in each model, TEMBEXA treatment resulted in statistically significant survival benefit versus placebo following delayed treatment after animals were infected with a lethal viral dose.
  • Most recently, the Company obtained FDA approval for brincidofovir as a medical countermeasure for the treatment of smallpox.
  • TEMBEXA is indicated for the treatment of human smallpox disease caused by variola virus in adult and pediatric patients, including neonates.
  • TEMBEXA is not indicated for the treatment of diseases other than human smallpox disease.

Aethlon Medical Publishes Case Studies of Two Critically Ill COVID-19 Patients Treated with the Hemopurifier®

Retrieved on: 
Thursday, June 3, 2021

SAN DIEGO, June 3, 2021 /PRNewswire/ --Aethlon Medical, Inc. (Nasdaq: AEMD), a medical device technology company focused on unmet needs in global health, today announced the publication of a pre-print manuscript highlighting two case studies of critically ill COVID-19 patients treated with the Aethlon Hemopurifier.

Key Points: 
  • SAN DIEGO, June 3, 2021 /PRNewswire/ --Aethlon Medical, Inc. (Nasdaq: AEMD), a medical device technology company focused on unmet needs in global health, today announced the publication of a pre-print manuscript highlighting two case studies of critically ill COVID-19 patients treated with the Aethlon Hemopurifier.
  • The manuscript describes the use of the Hemopurifier for a total of nine sessions in two critically ill COVID-19 patients.
  • This patient received eight Hemopurifier treatments without complications and eventually was weaned from a ventilator and was discharged from the hospital.
  • "Given the success of the Hemopurifier as a treatment for Ebola patients, we remain optimistic about our ongoing work in the treatment of COVID-19 patients.

Chimerix to Present at Jefferies Virtual Healthcare Conference

Retrieved on: 
Tuesday, May 25, 2021

DURHAM, N.C., May 25, 2021 (GLOBE NEWSWIRE) -- Chimerix(NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that Mike Sherman, Chief Executive Officer of Chimerix, will present a corporate overview at the Jefferies Virtual Healthcare Conference onTuesday, June 1, 2021at10:00 a.m.

Key Points: 
  • DURHAM, N.C., May 25, 2021 (GLOBE NEWSWIRE) -- Chimerix(NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that Mike Sherman, Chief Executive Officer of Chimerix, will present a corporate overview at the Jefferies Virtual Healthcare Conference onTuesday, June 1, 2021at10:00 a.m.
  • A live audio webcast of the chat will be available on the Investor Relations section ofChimerix'swebsite at ir.chimerix.com , where it will be archived for approximately 90 days.
  • Chimerix is a development-stage biopharmaceutical company dedicated to accelerating the advancement of innovative medicines that make a meaningful impact in the lives of patients living with cancer and other serious diseases.
  • The Companys three most advanced clinical-stage development programs are brincidofovir (BCV), ONC201 and dociparstat sodium (DSTAT).

AIkido Pharma Has Pending Data Results on June 4th, with Strongest Balance Sheet in Its History While Trading Below Cash

Retrieved on: 
Thursday, May 20, 2021

Novartis recently announced positive results in Phase III clinical trials.

Key Points: 
  • Novartis recently announced positive results in Phase III clinical trials.
  • This assumption is reinforced by the test results coming back from Novartis.
  • The study includes both novel and repurposed drugs.\nThe anti-viral program is a continuing mission to find treatment options for Coronavirus, Influenza, and Ebola.
  • Researchers have already identified a SKI complex as a potential broad-spectrum antiviral target with a functional link to viral proteins.\nEarly results from the project are encouraging.

Chimerix Announces Upcoming Presentations at the American Society of Clinical Oncology 2021 Annual Meeting

Retrieved on: 
Wednesday, May 19, 2021

Our three most advanced clinical-stage development programs are brincidofovir (BCV), ONC201 and dociparstat sodium (DSTAT).

Key Points: 
  • Our three most advanced clinical-stage development programs are brincidofovir (BCV), ONC201 and dociparstat sodium (DSTAT).
  • BCV is an antiviral drug candidate developed as a potential medical countermeasure for smallpox and is currently under review for regulatory approval in the United States.
  • ONC201 is currently in a registrational clinical program for recurrent H3 K27M-mutant glioma and a blinded independent central review is expected later this year.
  • DSTAT is in development as a potential first-line therapy in acute myeloid leukemia and as a potential treatment for acute lung injury in hospitalized COVID-19 patients.\n'

Chimerix to Present at Cowen and Company 2nd Annual Virtual Oncology Innovation Summit

Retrieved on: 
Thursday, May 13, 2021

Our three most advanced clinical-stage development programs are brincidofovir (BCV), ONC201 and dociparstat sodium (DSTAT).

Key Points: 
  • Our three most advanced clinical-stage development programs are brincidofovir (BCV), ONC201 and dociparstat sodium (DSTAT).
  • BCV is an antiviral drug candidate developed as a potential medical countermeasure for smallpox and is currently under review for regulatory approval in the United States.
  • ONC201 is currently in a registrational clinical program for recurrent H3 K27M-mutant glioma and a blinded independent central review is expected later this year.
  • DSTAT is in development as a potential first-line therapy in acute myeloid leukemia and as a potential treatment for acute lung injury in hospitalized COVID-19 patients.\n"

Quercis Announces Special Protocol Assessment Agreement with U.S. Food and Drug Administration

Retrieved on: 
Tuesday, May 4, 2021

Quercis Pharma is advancing a development pipeline of late-stage clinical studies that focus on the prevention of VTE in cancer patients.

Key Points: 
  • Quercis Pharma is advancing a development pipeline of late-stage clinical studies that focus on the prevention of VTE in cancer patients.
  • In addition, Quercis targets other diseases associated with thrombotic events, such as sickle cell disease (SCD), Ebola and COVID-19.
  • The Company\'s lead drug candidate acts as an antithrombotic with significantly lower risk of adverse events than existing treatments.
  • In addition, the Company is preparing to conduct a number of studies for the treatment of SCD (Phase 2) and COVID-19 (Phase 2/3).\n'